Coiro V, Chiodera P, Volpi R, d'Amato L, Camellini L, Rossi G, Pignatti D, Butturini U
J Endocrinol Invest. 1986 Feb;9(1):27-30. doi: 10.1007/BF03348058.
The effect of pirenzepine, a specific muscarinic cholinergic receptor antagonist, on insulin and glucagon responses to an intravenous injection of glucose was investigated in eight normal adult subjects. These volunteers received two iv glucose tolerance tests (0.33 g/kg) before and after the oral administration of 125 mg of pirenzepine (three doses of 25 mg during the day before the experiment and a fourth dose of 50 mg 2 h before glucose injection). Treatment with pirenzepine neither altered basal blood glucose levels nor affected glucose tolerance after the injection of the glucose load. In addition, it did not modify basal plasma insulin and glucagon levels and the decrement of glucagon in response to glucose injection. In contrast, pirenzepine significantly decreased insulin release induced by glucose administration. In man, during the present experimental conditions, the muscarinic cholinergic system modulates insulin, but not glucagon response to an iv glucose injection.
在8名正常成年受试者中研究了特异性毒蕈碱胆碱能受体拮抗剂哌仑西平对静脉注射葡萄糖后胰岛素和胰高血糖素反应的影响。这些志愿者在口服125 mg哌仑西平之前和之后接受了两次静脉葡萄糖耐量试验(0.33 g/kg)(在实验前一天分三次给予25 mg剂量,在葡萄糖注射前2小时给予第四次50 mg剂量)。哌仑西平治疗既未改变基础血糖水平,也未影响注射葡萄糖负荷后的葡萄糖耐量。此外,它没有改变基础血浆胰岛素和胰高血糖素水平以及注射葡萄糖后胰高血糖素的下降。相比之下,哌仑西平显著降低了葡萄糖给药诱导的胰岛素释放。在人体中,在当前实验条件下,毒蕈碱胆碱能系统调节胰岛素,但不调节对静脉注射葡萄糖的胰高血糖素反应。